Dublin, Oct. 11, 2017 -- The "High Throughput Screening Market - Global Opportunity Analysis And Industry Forecasts (2017-2022)" report has been added to Research and Markets' offering.
Global High Throughput Screening Market is expected to reach USD 21,911.2 million by 2022 supported by a CAGR of 8.0% during the forecast period of 2017 to 2022.
The global high throughput screening market is mainly driven by the increasing adoption of innovative approaches in pharmaceutical and biotechnology companies, growing investment by private equity firms and venture capitalists, rising government funding for various R&D activities, increasing healthcare spending, and technological advancements. Further, growing research in toxicology and stem cell research provide significant opportunities in this market. However, high cost for HTS, intricacy in the field of assay development, and government regulations for drug development obstructs the growth of this market to some extent.
Geographically, the global high throughput screening market is segmented into five major regions, namely North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. These regions are further analysed at a country level with the detailed qualitative and quantitative analysis. North America accounted for the major share in the global high throughput screening market in 2016, followed by Asia-Pacific, and Europe.
The major share of the North American region is mainly attributed to the growing elderly population and increased Research and development expenditure in biopharmaceuticals and biotechnology industries. On the other hand, Asia-Pacific region is projected to grow at a fastest CAGR during the forecast period, due to increasing population, rising prevalence of various diseases, and growing R&D funding for the drug discovery and development.
Key Topics Covered:
1. Introduction
1.1. Market Ecosystem
1.2. Currency and Limitations
1.2.1. Currency
1.2.2. Limitations
1.3. Key Stakeholders
2. Research Methodology
2.1. Research Process
2.1.1. Secondary Research
2.1.2. Primary Research
2.1.3. Market Size Estimation
3. Executive Summary
4. Market Insights
4.1. Introduction
4.2. Market Dynamics
4.2.1. Drivers
4.2.1.1. Increasing Adoption of Innovative Approaches in Pharmaceutical and Biotechnology Companies
4.2.1.2. Increasing Investment by Private Equity Firms and Venture Capitalists
4.2.1.3. Rising Government Initiatives and Funding For R&D
4.2.1.4. Increasing Healthcare Spending
4.2.1.5. Technological Advancements
4.2.2. Restraints
4.2.2.1. High Cost of HTS
4.2.2.2. Intricacy in the Field of Assay Development
4.2.2.3. Government Regulations For Drug Development
4.2.3. Opportunities
4.2.3.1. Growing Toxicology and Stem Cell Research
4.3. Key industry Trends
4.3.1. Increasing Consolidation and Competition Among Vendors
4.3.2. Improved Automation and Miniaturization of HTS Techniques
5. High Throughput Screening Market, by Technology
5.1. Introduction
5.2. Cell-Based Assays
5.2.1. 2D Cell Culture
5.2.2. 3D Cell Culture
5.2.2.1. Scaffold Based Technology
5.2.2.1.1. Natural Polymer Hydrogels
5.2.2.1.1.1. Collagen
5.2.2.1.1.2. Gelatin
5.2.2.1.1.3. Hyaluronic Acid
5.2.2.1.1.4. Alginate
5.2.2.1.2. Synthetic Polymers
5.2.2.1.3. Solid Scaffolds
5.2.2.2. Scaffold Free Technology
5.2.2.2.1. Hanging Drop Plates
5.2.2.2.2. Microfluidics
5.2.2.2.3. Rotating Wall Vessel
5.2.2.2.4. Other Scaffold Free Technologies
5.2.3. Perfusion Cell Culture
5.3. Ultra High Throughout Screening
5.4. Label Free Technology
5.5. Lab On A Chip
6. High Throughput Screening Market, by Product and Services
6.1. Introduction
6.2. Consumables & Reagents
6.3. Instruments
6.3.1. Sample Preparation Instruments & Accessories
6.3.2. Liquid Handling Instruments
6.3.3. Readers
6.3.4. Other Instruments
6.4. Software & Services
7. High Throughput Screening Market, by Application
7.1. Introduction
7.2. Stem Cell Research
7.3. Toxicology Assessment
7.4. Target Identification
7.5. Primary Screening
8. High Throughput Screening Market, by End User
8.1. Introduction
8.2. Pharmaceuticals and Biotechnology Industry
8.3. Academics and Research institutes
8.4. Contract Research organizations
8.5. Other End Users
9. High Throughput Screening Market, by Geography
10. Competitive Landscape
11. Company Profiles
- AXXAM S.p.A. (Italy)
- Agilent technologies Inc. (U.S.)
- Aurora Biomed Inc. (Canada)
- Bio-Rad Laboratories Inc.(U.S.)
- Charles River Laboratories International Inc. (U.S.)
- Danaher Corporation (U.S.)
- Hamilton Company (U.S.)
- Merck KGaA (Germany)
- Perkin Elmer (U.S.)
- Tecan Trading AG (Switzerland)
- Thermo Fisher Scientific Inc. (U.S.)
For more information about this report visit https://www.researchandmarkets.com/research/r2vtss/high_throughput
CONTACT: Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Drug Discovery


Bill Ackman Eyes New Fund to Bet Against Market Complacency
Pony.ai, Uber, and Verne Launch Europe's First Commercial Robotaxi Service in Zagreb
Bank of America Identifies Top Asia-Pacific Semiconductor Stocks Poised for AI-Driven Growth
Alibaba Shares Slide as Jefferies Slashes Price Target Over AI Spending and Business Losses
Lumentum Holdings Rides AI Wave With Order Book Filled Through 2028
MATCH Act: How New U.S. Chip Legislation Could Freeze China's Semiconductor Ambitions
NIO ES9 SUV Launch Sends HK Shares Down 7% Despite Bold Pricing Strategy
AI Deradicalization Tools: How Chatbots Could Help Combat Violent Extremism Online
San Francisco Suspect Arrested After Molotov Cocktail Attack on OpenAI CEO Sam Altman's Home
Chalco Stock Surges as Q1 2025 Profit Forecast Jumps Up to 58%
TSMC Posts Strong Q1 2025 Revenue, Riding AI Chip Demand Wave
Bendigo and Adelaide Bank Posts Strong Q3 Earnings, Announces AI-Driven Job Cuts
Rio Tinto's California Boron Assets Attract Over a Dozen Bidders, Valued at Up to $2 Billion
Chinese Cars in Europe: Consumer Trust Is Shifting Fast
Disney Plans to Cut 1,000 Jobs Amid Ongoing Restructuring Efforts
Foreign Investors Pour $18.65 Billion into Japanese Stocks Amid Market Stabilization
Abbott Laboratories Ordered to Pay $53 Million in Premature Infant Formula Lawsuit 



